The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Endogenous c-MYC (MYC) has been reported to be a potential pharmacological target to trigger ubiquitous tumor regression of pancreatic neuroendocrine tumors (PanNETs) and lung tumors. Recently inhibitors of bromodomain and extra-terminal (BET) family proteins have shown antitumor effects through the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, C, Laddha, S V, Tang, L, Vosburgh, E, Levine, A J, Normant, E, Sandy, P, Harris, C R, Chan, C S, Xu, E Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237236/
https://www.ncbi.nlm.nih.gov/pubmed/25299775
http://dx.doi.org/10.1038/cddis.2014.396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237236/
https://www.ncbi.nlm.nih.gov/pubmed/25299775
http://dx.doi.org/10.1038/cddis.2014.396

Ejemplares similares